Skip to main content
Erschienen in: World Journal of Urology 10/2021

12.05.2021 | Original Article

Fragility index of urological literature regarding medical expulsive treatment

verfasst von: Lazaros Tzelves, Nikolaos Chatzikrachtis, Lazaros Lazarou, Panagiotis Mourmouris, Alexandros Pinitas, Kimon Tsirkas, Orestis Petropoulos, Marinos Berdempes, Georgios Feretzakis, Ioannis Glykas, Charalampos Fragkoulis, Ioannis Varkarakis, Andreas Skolarikos

Erschienen in: World Journal of Urology | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The role of medical expulsive treatment (MET) is controversial. Fragility index is an additional metric to assess randomized controlled trials (RCTs) outcome validity and indicates how many patients would be required to convert a trial from being statistically significant, to not significant. The larger is the FI, the better the trial’s data. The aim of this study is to assess FI of RCTs regarding MET for ureteral stones.

Materials and methods

A systematic literature search was performed. RCTs, reporting stone expulsion as a dichotomous outcome, showing statistical significance were eligible. FI (the number of patients needed to change from a non-event to event group, to lose statistical significance) and Fragility quotient (FI divided by total sample size), were calculated while Pearson’s correlation and Mann–Whitney U test were used as appropriate.

Results

Thirty-six RCTs were eligible, with median FI = 3.5 and fragility quotient = 0.042, median sample size = 81, median journal impact factor = 1.73 and median reported p value = 0.008. In 33.3% of the studies, number of patients lost during follow-up was larger than FI, while in 13.89% of the studies, FI was 0, indicating use of inappropriate statistical method. Pearson’s correlation showed significant positive association between FI and sample size (r = 0.981), number of events (r = 0.982) and impact factor (r = 0.731), while no association was found with p value or publication year.

Conclusions

In this analysis, a calculated FI of 3.5 indicates that findings from RCTs on MET for ureteral stones are fragile and should be interpreted in combination with clinical thinking and expertise.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Turney BW, Reynard JM, Noble JG, Keoghane SR (2012) Trends in urological stone disease. BJU Int 109(7):1082–1087CrossRef Turney BW, Reynard JM, Noble JG, Keoghane SR (2012) Trends in urological stone disease. BJU Int 109(7):1082–1087CrossRef
2.
Zurück zum Zitat Türk C, Petřík A, Sarica K, Seitz C, Skolarikos A, Straub M et al (2016) EAU guidelines on diagnosis and conservative management of urolithiasis. Eur Urol 69(3):468–474CrossRef Türk C, Petřík A, Sarica K, Seitz C, Skolarikos A, Straub M et al (2016) EAU guidelines on diagnosis and conservative management of urolithiasis. Eur Urol 69(3):468–474CrossRef
3.
Zurück zum Zitat Türk C, Petřík A, Sarica K, Seitz C, Skolarikos A, Straub M et al (2016) EAU guidelines on interventional treatment for urolithiasis. Eur Urol 69(3):475–482CrossRef Türk C, Petřík A, Sarica K, Seitz C, Skolarikos A, Straub M et al (2016) EAU guidelines on interventional treatment for urolithiasis. Eur Urol 69(3):475–482CrossRef
4.
Zurück zum Zitat Mourmouris P, Tzelves L, Skolarikos A (2020) Complications after active stone removal. Curr Opin Urol 30(2):135–143CrossRef Mourmouris P, Tzelves L, Skolarikos A (2020) Complications after active stone removal. Curr Opin Urol 30(2):135–143CrossRef
5.
Zurück zum Zitat Vassileva J, Zagorska A, Basic D, Karagiannis A, Petkova K, Sabuncu K et al (2020) Radiation exposure of patients during endourological procedures: IAEA-SEGUR study. J Radiol Protect 40(4):1390–1405CrossRef Vassileva J, Zagorska A, Basic D, Karagiannis A, Petkova K, Sabuncu K et al (2020) Radiation exposure of patients during endourological procedures: IAEA-SEGUR study. J Radiol Protect 40(4):1390–1405CrossRef
6.
Zurück zum Zitat Vassileva J, Zagorska A, Karagiannis A, Petkova K, Sabuncu K, Saltirov I et al (2020) Radiation exposure of surgical team during endourological procedures: International Atomic Energy Agency-South-Eastern European Group for Urolithiasis Research Study. J Endourol. (Online Ahead of Print) Vassileva J, Zagorska A, Karagiannis A, Petkova K, Sabuncu K, Saltirov I et al (2020) Radiation exposure of surgical team during endourological procedures: International Atomic Energy Agency-South-Eastern European Group for Urolithiasis Research Study. J Endourol. (Online Ahead of Print)
7.
Zurück zum Zitat Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR et al (2014) Medical management of kidney stones: AUA guideline. J Urol 192(2):316–324CrossRef Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR et al (2014) Medical management of kidney stones: AUA guideline. J Urol 192(2):316–324CrossRef
8.
Zurück zum Zitat Tzelves L, Mourmouris P, Skolarikos A (2021) Comparison of current guidelines on medical management of stone disease. Arch Esp Urol 74(1):171–182PubMed Tzelves L, Mourmouris P, Skolarikos A (2021) Comparison of current guidelines on medical management of stone disease. Arch Esp Urol 74(1):171–182PubMed
9.
Zurück zum Zitat Campschroer T, Zhu X, Vernooij RWM, Lock T (2018) α-blockers as medical expulsive therapy for ureteric stones: a Cochrane systematic review. BJU Int 122(6):932–945CrossRef Campschroer T, Zhu X, Vernooij RWM, Lock T (2018) α-blockers as medical expulsive therapy for ureteric stones: a Cochrane systematic review. BJU Int 122(6):932–945CrossRef
10.
Zurück zum Zitat Hollingsworth JM, Canales BK, Rogers MA, Sukumar S, Yan P, Kuntz GM et al (2016) Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ (Clinical research ed) 355:i6112 Hollingsworth JM, Canales BK, Rogers MA, Sukumar S, Yan P, Kuntz GM et al (2016) Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ (Clinical research ed) 355:i6112
11.
Zurück zum Zitat Türk C, Knoll T, Petřík A, Sarica K, Seitz C, Skolarikos A (2017) Grey Zones in Urolithiasis Guidelines. Eur Urol Focus 3(1):144–146CrossRef Türk C, Knoll T, Petřík A, Sarica K, Seitz C, Skolarikos A (2017) Grey Zones in Urolithiasis Guidelines. Eur Urol Focus 3(1):144–146CrossRef
12.
Zurück zum Zitat Tzelves L, Türk C, Skolarikos A (2021) European Association of Urology Urolithiasis Guidelines: Where Are We Going? Eur Urol Focus 7(1):34–38CrossRef Tzelves L, Türk C, Skolarikos A (2021) European Association of Urology Urolithiasis Guidelines: Where Are We Going? Eur Urol Focus 7(1):34–38CrossRef
13.
Zurück zum Zitat Pickard R, Starr K, MacLennan G, Lam T, Thomas R, Burr J et al (2015) Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. The Lancet 386(9991):341–349CrossRef Pickard R, Starr K, MacLennan G, Lam T, Thomas R, Burr J et al (2015) Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. The Lancet 386(9991):341–349CrossRef
14.
Zurück zum Zitat Sur RL, Shore N, L’Esperance J, Knudsen B, Gupta M, Olsen S et al (2015) Silodosin to facilitate passage of ureteral stones: a multi-institutional, randomized, double-blinded, placebo-controlled trial. Eur Urol 67(5):959–964CrossRef Sur RL, Shore N, L’Esperance J, Knudsen B, Gupta M, Olsen S et al (2015) Silodosin to facilitate passage of ureteral stones: a multi-institutional, randomized, double-blinded, placebo-controlled trial. Eur Urol 67(5):959–964CrossRef
15.
Zurück zum Zitat Skolarikos A, Ghani KR, Seitz C, Van Asseldonk B, Bultitude MF (2017) Medical expulsive therapy in urolithiasis: a review of the quality of the current evidence. Eur Urol Focus 3(1):27–45CrossRef Skolarikos A, Ghani KR, Seitz C, Van Asseldonk B, Bultitude MF (2017) Medical expulsive therapy in urolithiasis: a review of the quality of the current evidence. Eur Urol Focus 3(1):27–45CrossRef
16.
Zurück zum Zitat Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed) 343:d5928CrossRef Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed) 343:d5928CrossRef
17.
Zurück zum Zitat Walsh M, Srinathan SK, McAuley DF, Mrkobrada M, Levine O, Ribic C et al (2014) The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index. J Clin Epidemiol 67(6):622–628CrossRef Walsh M, Srinathan SK, McAuley DF, Mrkobrada M, Levine O, Ribic C et al (2014) The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index. J Clin Epidemiol 67(6):622–628CrossRef
18.
Zurück zum Zitat Narayan VM, Gandhi S, Chrouser K, Evaniew N, Dahm P (2018) The fragility of statistically significant findings from randomised controlled trials in the urological literature. BJU Int 122(1):160–166CrossRef Narayan VM, Gandhi S, Chrouser K, Evaniew N, Dahm P (2018) The fragility of statistically significant findings from randomised controlled trials in the urological literature. BJU Int 122(1):160–166CrossRef
19.
Zurück zum Zitat Rickard M, Lorenzo AJ, Hannick JH, Blais AS, Koyle MA, Bägli DJ (2019) Over-reliance on P values in urology: fragility of findings in the hydronephrosis literature calls for systematic reporting of robustness indicators. Urology 133:204–210CrossRef Rickard M, Lorenzo AJ, Hannick JH, Blais AS, Koyle MA, Bägli DJ (2019) Over-reliance on P values in urology: fragility of findings in the hydronephrosis literature calls for systematic reporting of robustness indicators. Urology 133:204–210CrossRef
20.
Zurück zum Zitat Khan MS, Ochani RK, Shaikh A, Usman MS, Yamani N, Khan SU et al (2019) Fragility index in cardiovascular randomized controlled trials. Circ Cardiovasc Qual Outcomes. 12(12):e005755CrossRef Khan MS, Ochani RK, Shaikh A, Usman MS, Yamani N, Khan SU et al (2019) Fragility index in cardiovascular randomized controlled trials. Circ Cardiovasc Qual Outcomes. 12(12):e005755CrossRef
21.
Zurück zum Zitat Farland LV, Correia KF, Wise LA, Williams PL, Ginsburg ES, Missmer SA (2016) P-values and reproductive health: what can clinical researchers learn from the American Statistical Association? Human Reprod (Oxford, England) 31(11):2406–2410CrossRef Farland LV, Correia KF, Wise LA, Williams PL, Ginsburg ES, Missmer SA (2016) P-values and reproductive health: what can clinical researchers learn from the American Statistical Association? Human Reprod (Oxford, England) 31(11):2406–2410CrossRef
22.
Zurück zum Zitat Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J et al (2011) The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis—a simulation study. PLoS ONE 6(10):e25491-eCrossRef Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J et al (2011) The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis—a simulation study. PLoS ONE 6(10):e25491-eCrossRef
23.
Zurück zum Zitat Majeed M, Agrawal R, Attar BM, Kamal S, Patel P, Omar YA et al (2020) Fragility index: how fragile is the data that support the American College of Gastroenterology guidelines for the management of Crohn’s disease? Eur J Gastroenterol Hepatol 32(2):193–198CrossRef Majeed M, Agrawal R, Attar BM, Kamal S, Patel P, Omar YA et al (2020) Fragility index: how fragile is the data that support the American College of Gastroenterology guidelines for the management of Crohn’s disease? Eur J Gastroenterol Hepatol 32(2):193–198CrossRef
24.
Zurück zum Zitat Shochet LR, Kerr PG, Polkinghorne KR (2017) The fragility of significant results underscores the need of larger randomized controlled trials in nephrology. Kidney Int 92(6):1469–1475CrossRef Shochet LR, Kerr PG, Polkinghorne KR (2017) The fragility of significant results underscores the need of larger randomized controlled trials in nephrology. Kidney Int 92(6):1469–1475CrossRef
25.
Zurück zum Zitat Evaniew N, Files C, Smith C, Bhandari M, Ghert M, Walsh M et al (2015) The fragility of statistically significant findings from randomized trials in spine surgery: a systematic survey. Spine J 15(10):2188–2197CrossRef Evaniew N, Files C, Smith C, Bhandari M, Ghert M, Walsh M et al (2015) The fragility of statistically significant findings from randomized trials in spine surgery: a systematic survey. Spine J 15(10):2188–2197CrossRef
Metadaten
Titel
Fragility index of urological literature regarding medical expulsive treatment
verfasst von
Lazaros Tzelves
Nikolaos Chatzikrachtis
Lazaros Lazarou
Panagiotis Mourmouris
Alexandros Pinitas
Kimon Tsirkas
Orestis Petropoulos
Marinos Berdempes
Georgios Feretzakis
Ioannis Glykas
Charalampos Fragkoulis
Ioannis Varkarakis
Andreas Skolarikos
Publikationsdatum
12.05.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 10/2021
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-021-03725-2

Weitere Artikel der Ausgabe 10/2021

World Journal of Urology 10/2021 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.